Media stories about Deciphera Pharmaceuticals (NASDAQ:DCPH) have trended somewhat positive on Monday, according to Accern Sentiment. The research group ranks the sentiment of media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Deciphera Pharmaceuticals earned a coverage optimism score of 0.15 on Accern’s scale. Accern also gave media stories about the company an impact score of 45.4265895402245 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Shares of Deciphera Pharmaceuticals (NASDAQ:DCPH) opened at $25.04 on Monday. Deciphera Pharmaceuticals has a 12-month low of $15.15 and a 12-month high of $29.98.
Several analysts have commented on DCPH shares. Zacks Investment Research raised shares of Deciphera Pharmaceuticals from a “hold” rating to a “buy” rating and set a $22.00 price objective on the stock in a research report on Monday, December 25th. BidaskClub raised shares of Deciphera Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, January 3rd. Finally, B. Riley started coverage on shares of Deciphera Pharmaceuticals in a research report on Friday, February 16th. They issued a “buy” rating and a $43.00 price objective on the stock. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. Deciphera Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $41.14.
Deciphera Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is developing drugs to improve the lives of cancer patients. Its drug candidate includes DCC-2618, DCC-3014 and Rebastinib. Its proprietary kinase switch control inhibitor platform, inhibit the activation of kinases.
Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.